Radiotherapy-related changes in serum proteome patterns of head and neck cancer patients; the effect of low and medium doses of radiation delivered to large volumes of normal tissue
© Widłak et al.; licensee BioMed Central Ltd. 2013
Received: 28 June 2013
Accepted: 25 November 2013
Published: 5 December 2013
Conformal intensity-modulated radiation therapy (IMRT) involves irradiation of large volume of normal tissue with low and medium doses, biological relevance of which is not clear yet. Serum proteome features were used here to study the dose-volume effects in patients irradiated with IMRT due to head and neck cancer.
Blood samples were collected before and during RT, and also about one month and one year after the end of RT in a group of 72 patients who received definitive treatment. Serum proteome profiles were analyzed using MALDI-ToF mass spectrometry in 800–14,000 Da range.
Major changes in serum proteome profiles were observed between pre-treatment samples and samples collected one month after RT. Radiation-related changes in serum proteome features were affected by low-to-medium doses delivered to a large fraction of body mass. Proteome changes were associated with intensity of acute radiation toxicity, indicating collectively that RT-related features of serum proteome reflected general response of patient’s organism to irradiation. However, short-term dose-related changes in serum proteome features were not associated significantly with the long-term efficacy of the treatment.
The effects of low and medium doses of radiation have been documented at the level of serum proteome, which is a reflection of the patient’s whole body response.
KeywordsDose effects Head and neck cancer IMRT Radiation toxicity Serum proteome
Radiotherapy (RT), either alone or in combination with chemotherapy, is an effective treatment of different types of cancer, including head and neck squamous cell carcinoma, which allows preserving the structure and function of a target organ. Successful RT of patients with advanced cancer usually requires aggressive methods of treatment, which include accelerated fractionation successfully implemented in radical treatment of head and neck cancer[1, 2]. However, application of such a treatment increases risk of unacceptable toxicity to normal tissue, where radiation induces damage leading to acute and/or late injury reactions.
Differences in repair of radiation damage between tumor and normal tissue are the main biological concept of radiotherapy, and until the end of 20th century radiation therapy was applied using two opposite radiation fields with similar doses delivered to tumor and normal tissue (dose fractionation was used to reduce toxicity of such a treatment). In recent two decades development of advanced 3D radiation treatment planning systems and technological progress in construction of linear accelerators with multileaf collimators (MLC) allowed on real differentiation of radiation doses between tumor and normal tissue. The main concept of conformal radiotherapy is based on the focusing of several radiation fields in the target volume, allowing a higher dose of radiation to be delivered to the tumor and (intentionally) reducing its toxicity to the surrounding normal tissues. The intensity-modulated radiation therapy (IMRT) is the next step in optimization of radiation dose. This technique takes advantage of treatment planning systems by calculating the optimal position of MLC during irradiation, which results in better differentiation of dose between normal tissue and tumor. Introduction of many non-coplanar radiation fields results in irradiation of larger volumes of normal tissues with small doses of radiation comparing to two-field technique, yet the increase in volume of patient’s body exposed to low doses of radiation is a potential drawback of IMRT. Theoretically irradiation with small doses should not introduce substantial damage to normal tissues because of a threshold in the dose-effect relationship. On the other hand, however, the whole body effect of irradiation using IMRT has not been studied in depth because of the lack of existing end-points and biological markers of irradiation to small doses. In fact, the only concern regarding IMRT that has been examined so far is a treatment of children in the context of a risk of secondary cancers. Hence, documenting the possible biological effects of irradiation of large masses of normal tissues with low and medium doses is an urgent issue rev. in:[5, 6].
The low-molecular-weight fraction of serum/plasma proteome (up to 15,000 Da) appears to be a promising source of novel biomarkers rev. in:[7, 8]. Several published studies on mass spectrometry-based profiling of this fraction of blood have revealed multi-peptide signatures that could be used for detection and/or classification of cancer. Noteworthy, several components of proposed cancer signatures, especially those characteristic for advanced cancer, were identified as fragments of blood proteins involved in general response of patient’s organism to the disease. Of note, profiling of serum/plasma proteome revealed features that reflected general reaction of the patient’s whole body to anticancer treatment[8–10]. A few published works used this approach aiming to detect radiation-related effects in locally irradiated cancer patients. These works reported changes in serum proteome profiles between pre-exposure and post-exposure samples, and found differences between samples from patients exposed to different doses of radiation[11, 12]. Although both reports documented the influence of radiation doses on therapy-related changes in the serum proteome, they focused on the radiation doses delivered to tumor volume. Here, we hypothesized that the whole body response of a patient to the treatment may be related not only to high doses delivered to tumor volume but also to low- and medium-doses delivered during IMRT to large volume of normal tissue.
Characteristics of patient group
Seventy two patients with head and neck squamous cell cancer were enrolled into this prospective study; all participants were Caucasians (51 men), 40–80 years old (median age 60 years), mostly current smokers (85%) and alcohol consumers (83%). Cancer was located at either oropharynx (31), hypopharynx (8) or larynx (33); primary tumor stage was scored as: T1 (7%), T2 (43%), T3 (34%) and T4 (16%); 51% of N0. All patients were subjected to IMRT using 6 MeV photons (1.8 Gy daily fraction doses according to the continuous accelerated irradiation scheme, CAIR). Total radiation doses delivered to gross tumor volume (GTV) were in the 66.6-73.8 Gy range (median 72 Gy), overall treatment time was between 38–49 days (median 41 days). Neither surgery nor induction/concomitant chemotherapy was applied to patients enrolled in the study. The acute mucosal reaction (AMR) was assessed using the Dische score system[13, 14] each 3–5 days during the RT. Three-year recurrence-free survival was observed in 36 patients, while treatment failure due to local recurrence, distant metastases and/or second tumor was noted in 25 patients during the same follow-up. Four consecutive blood samples (5 ml) were collected from each patient: pre-treatment sample A (within one week before RT; 72 patients); within-treatment sample B (9–23 days after the start of RT; median 15 days; 72 patients); post-treatment sample C (16–73 days after the end of RT; median 34 days; 68 patients) and post-treatment sample D (52–714 days after the end of RT; median 460 days, 59 patients). The study was approved by local Ethics Committee at the Cancer Center in Gliwice and all participants provided informed consent indicating their conscious and voluntary participation.
Irradiated volumes and related radiation doses were read from treatment plans that based on CT scans of head, neck and upper thorax region (using the ECLIPSE radiation therapy planning system). Because the CT scans always include region containing all radiation fields assessment of doses and volumes is straightforward. The dose-volume histograms (DVH, see below) represent volume of irradiated tissue irradiated with specific dose level (according to the treatment plans), which is an important element of evaluation of IMRT plan.
Sample preparation and serum mass profile acquisition
Collected blood was incubated for 30 min. at room temperature to allow clotting, and then centrifuged at 1000 g for 10 min. to remove the clot. The serum was aliquoted and stored at -70°C. Directly before analysis samples were diluted 1:5 with mixture of acetonitrile (20%) and ammonium bicarbonate (250 mM), and then albumin and other large-molecular-weight proteins were removed by centrifugation (30 minutes, 3000 g) through AmiconUltra filters with 50 kDa cut-off membrane (Millipore). Each sample was loaded onto a C18 ZipTip micro-column by passing it through repeatedly 15 times until saturation, then column was washed with water and eluted with 1 μl of matrix solution (saturated solution of alpha-cyano-4-hydroxycinnamic acid in 50% ACN/H2O and 0.1% TFA) directly onto the 600 μm AnchorChip (Bruker Daltonics) plate. Samples were analyzed using an Ultraflextreme MALDI-ToF spectrometer (Bruker Daltonics, Bremen, Germany); the analyzer worked in the linear mode and positive ions were recorded in the mass range between 800 and 14,000 Da. ZipTip extraction/loading was repeated twice for each sample and for each spot two averaged spectra were recorded (i.e. four spectra were acquired for each sample). All samples were analyzed in a random sequence to avoid a possible batch effect.
Analysis of mass profiles
The pre-processing of spectra, which included baseline removal, alignment and averaging of technical repeats, and normalization of the total ion current (TIC), was performed according to procedures considering to be standard in the field. In the second step the spectral components, which reflected [M+H]+ peptide ions recorded at defined m/z values, were identified using decomposition of mass spectra into their Gaussian components followed by several post-processing steps as described in more details elsewhere[16, 17]. The average spectrum was decomposed into a sum of Gaussian bell-shaped curves by using a variant of the expectation maximization (EM) algorithm and Bayesian Information Criterion (BIC) for model selection. The initial set of 366 Gaussian components, defined by their mean values and standard deviations, was further processed to merge overlapping components (components homogenous in variance and with main values closer than 0.1% of the m/z value) and to remove components presumably representing the residual baseline (components with coefficient of variation bigger than 25%), which resulted in dimension reduction to 319 Gaussian components. The final 319 Gaussian components were used to compute features of registered spectra (termed spectral components afterward) for all samples by the operations of convolutions with Gaussian masks. The knowledge base EPO-KB (Empirical Proteomic Ontology Knowledge Base), which links m/z values to known peptide/proteins, was used for hypothetical annotation of spectral components.
For each serum component the normality of distribution of changes was assessed using the Lilliefors test to provide optimal tools for statistical analysis. Either the t-test or the Wilcoxon test corrected for multiple testing with false discovery rate (FDR) estimation was applied for analyzing changes in abundances of spectral components. Correlation between abundance of spectral components and parameters reflecting absorbed doses of radiation was analyzed using either the Pearson’s correlation coefficient or the Spearman’s rank correlation coefficient (depending on the type of distribution). Total radiation energy absorbed by patient’s body was estimated from the individual DVH generated during the treatment planning by calculating its integral over dose. For the analysis of dose/volume effect doses corresponding to deciles of the area under curve of the averaged DVH were selected (see below) Correlation between maximal intensity of the AMR and abundance of spectral components or radiation doses was analyzed using the Spearman’s rank correlation coefficient.
Exposure to ionizing radiation resulted in gross changes of the low-molecular-weight component of serum proteome
Radiation-induced changes in the serum proteome profiles could be reversed during long time follow-up
Treatment-related changes in serum proteome profiles were associated with volumes of irradiated tissues and doses of radiation received by patients
Numbers of serum components correlated with GTV doses, total absorbed radiation energy (TARE) and maximum AMR intensity
Number of correlated components
Examples of components (m/z and hypothetical annotation)
4894, 6282 [CYTC], 9715
1192, 1209, 1266 [A4]
2110 [A4], 2994
1334 [FIBA], 1433, 5407 [S10A8]
Changes in serum proteome profiles were associated with toxicity of the treatment
Numbers of spectral components associated with efficacy of the treatment
Number of components
Examples of components (m/z and hypothetical annotation)
5737, 5755 [SAA1], 5765
1953, 2192 [HEPC], 2354, 2647, 3579
We showed here that local irradiation of patients during the course of head and neck cancer radiotherapy resulted in gross changes in the low-molecular-weight component of the serum proteome after the end of RT. The relatively smaller changes in the serum proteome that were detected during the first phase of RT could be explained by a lag period and/or certain dose threshold-requirements of radiation-induced processes. This observation was coherent with the results of a study performed on a smaller group of patients treated due to larynx cancer. In the present study we focused on dose effects and aimed to assess the importance of clinically low and intermediate doses of radiation delivered to large fractions of normal tissues. Two previous studies concerning the impact of local cancer irradiation on the serum proteome, which revealed the importance of radiation doses, focused on maximum doses delivered to tumor volume and based their conclusions on rather heterogenous clinical material[11, 12]. Here, we analyzed homogenous material obtained from a relatively large group of patients where no cancer surgery or chemotherapy was applied. Hence, the heterogeneous factors that could interfere with the obtained results were excluded. We observed that large overall extent of massive changes induced upon the irradiation apparently impaired ability to detect more refined quantitative correlations with radiation doses. Nevertheless, association of specific changes in abundance of serum components with doses and volumes of irradiated tissue was found. Although correlations identified between specific proteome features and different parameters reflecting radiation doses possess moderate statistical power when analyzed separately, reliable conclusions could be drawn based on the general patterns of observed association. We noted that effects of low-to-medium doses delivered to large volumes of normal tissue were apparently more frequent than effects of high doses delivered to target volume of tumor, and concluded that effects of such low-to-medium doses could be observed at the level of whole body response to radiotherapy.
We found that massive changes of serum proteome profiles observed during and soon after the end of radiotherapy, i.e. “early” effects of irradiation, were somehow reversed/compensated by “late” changes, observed at longer times of the follow-up. This apparently reflected process of return to the initial steady-state level (e.g. accumulation and subsequent healing of radiation damage). However, “late” radiation-induced changes observed during the follow-up were relatively weaker and not always fully reversed the stronger changes induced during the treatment. As a consequence, radiation-related changes could be observed months after the end of radiotherapy and abundances of several serum components were significantly different when samples collected more than one year after the treatment, were compared to samples collected before the radiotherapy. Similar observation was made in a group of breast cancer patients where changes in serum proteome profiles related to the adjuvant radio/chemotherapy were detected one year after the treatment. Such results clearly indicated that toxic effects of anti-cancer therapy are long-lasting and could be detected as specific features of serum proteome many months after the treatment. Importantly, this finding indicates the possible applicability of MS-based analyses of serum proteome profiles in retrospective bio-dosimetry of radiation exposure. On the other hand, one should note that serum proteome components involved in a dose/volume-related “early” radiation response of the organism did not show significant association with long-term efficacy of the treatment (i.e. tumor eradication vs. re-growth) when a group of patients with similar prognosis treated with unified radiotherapy protocol was analyzed.
Model presented in current study is extremely complex and could be affected by many different processes ongoing in the patient’s organism. However, we assumed that accumulation and subsequent healing of radiation-induced damage (acute reactions, mucositis, hematological reactions, etc.) would have the major influence on general therapy-related changes observed at the level of serum proteome. In fact, we found an association of serum proteome features with the intensity of radiation-induced acute mucosal reaction, which was in accordance with the apparent correlation between the observed radiation toxicity and the doses of radiation delivered to normal tissues. We found the strongest correlation between the mucosal reaction and volume irradiated at 30-40 Gy (i.e., at 0.7-1.0 Gy dose fractions). Of note, changes of serum proteome profiles observed two weeks after the start of RT, which putatively accompanied escalation of mucosal reaction, also showed the most frequent correlations with volume of tissue irradiated at similar “intermediate” dose fractions (0.7-1.0 Gy). Several peptide ions registered in the low-molecular-weight fraction of serum proteome that changed their abundance in samples from irradiated patients were hypothetically annotated in the proteomic knowledge base EPO-KB as fragments of proteins related to the inflammation, immunity and defense. Among such proteins, there were acute phase proteins (fibrinogen, haptoglobin, hepcidin, SAA), complement factors (CO3, CO4A), protease inhibitors (AACT, ANT3, CYTC, ITIH4), cytokines (CCL13, CXCL7, OSTP, PLF4, S10AC) and antibacterial defensins (DEF1, DEF3, DEFB1) (see Additional file1: Table S1 and Table S7 for details). These processes are potentially involved in response to radiation, and several proteins related to acute phase and inflammation were previously reported in serum samples collected after radiotherapy of cancer patients. Hence, we postulate that radiation-induced features of the serum proteome, detected in post-treatment samples, correspond to the direct toxic effects of radiation and/or healing of the acute reaction.
Due to dosimetrical superiority of IMRT plans this treatment modality constantly replaces the more “traditional” radiotherapy techniques. Here, we observed that irradiation of large volumes of normal tissue with doses of radiation considered as “therapeutically irrelevant”, which is typical for IMRT, may have some biological effects. Their potential importance for output of the treatment is not as obvious, because exposure of increased volume of normal tissues could hypothetically be either detrimental (e.g. inflammation reactions related to radiation toxicity) or beneficial (e.g. radiation-induced stimulation of immune reactions). Hence, their clinical implications need to be carefully considered when complete data of long-term effects concerning the IMRT implemented in large cohorts of patients are available for analyses.
This is the first time that the effects of low and intermediate doses of radiation delivered to a large fraction of normal tissue have been documented at the level of the serum proteome. They apparently reflects the general response of patient’s organism to radiation, indicating potential biological relevance of therapeutically low doses during IMRT.
This work was supported by the Polish National Science Centre, Grant N402-450339 and 2011/01/B/NZ4/03563. MKH and KJ were supported by the European Social Fund within the INTERKADRA project UDA-POKL-04.01.01-00-014/10-00.
- Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J: Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006, 368: 843-854. 10.1016/S0140-6736(06)69121-6.View ArticlePubMedGoogle Scholar
- Skladowski K, Maciejewski B, Golen M, Tarnawski R, Slosarek K, Suwinski R: Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial. Int J Radiat Oncol Biol Phys. 2006, 66: 706-713. 10.1016/j.ijrobp.2006.05.026.View ArticlePubMedGoogle Scholar
- Epstein JB, Schubert MM: Oropharyngeal mucositis in cancer therapy. Oncology. 2003, 17: 1767-1779.PubMedGoogle Scholar
- Halperin EC, Perez CA, Brady LW: Perez and Brady’s Principles and Practice of Radiation Oncology. 2008, Philadelphia: Wolters Kluwer Health, Lippincott Williams & Wilkins, 5Google Scholar
- Deasy JO, Fowler JF: Radiobiology of IMRT. Intensity Modulated Radiation Therapy. A Clinical Perspective. Edited by: Mundt AJ, Roeske JC. 2005, Hamilton: BC Decker Inc, 53-74.Google Scholar
- De Neve W, De Gersem W, Madani I: Rational use of intensity-modulated radiation therapy: the importance of clinical outcome. Semin Radiat Oncol. 2012, 22: 40-49. 10.1016/j.semradonc.2011.09.003.View ArticlePubMedGoogle Scholar
- Liotta LA, Ferrari M, Petricoin EF: Clinical proteomics: written in blood. Nature. 2003, 425: 905-10.1038/425905a.View ArticlePubMedGoogle Scholar
- Solassol J, Jacot W, Lhermitte L, Boulle N, Maudelonde T, Mangé A: Clinical proteomics and mass spectrometry profiling for cancer detection. Expert Rev Proteomics. 2006, 3: 311-320. 10.1586/14789418.104.22.1681.View ArticlePubMedGoogle Scholar
- Palmblad M, Tiss A, Cramer R: Mass spectrometry in clinical proteomics – from the present to the future. Proteomics Clin Appl. 2009, 3: 6-17. 10.1002/prca.200800090.View ArticlePubMedGoogle Scholar
- Pietrowska M, Widlak P: MALDI-MS-based profiling of serum proteome: detection of changes related to progression of cancer and response to anticancer treatment. Int J Proteomics. 2012, 2012: e926427-View ArticleGoogle Scholar
- Ménard C, Johann D, Lowenthal M, Muanza T, Sproull M, Ross S: Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis. Cancer Res. 2006, 66: 1844-1850. 10.1158/0008-5472.CAN-05-3466.View ArticlePubMedGoogle Scholar
- Widlak P, Pietrowska M, Wojtkiewicz K, Rutkowski T, Wygoda A, Marczak L: Radiation-related changes in serum proteome profiles detected by mass spectrometry in blood of patients treated with radiotherapy due to larynx cancer. J Radiat Res. 2011, 52: 575-581. 10.1269/jrr.11019.View ArticlePubMedGoogle Scholar
- Dische S: The uniform reporting of treatment-related morbidity. Seminars Radiat Oncol. 1994, 4: 112-118. 10.1016/S1053-4296(05)80038-4.View ArticleGoogle Scholar
- Wygoda A, Maciejewski B, Skladowski K, Hutnik M, Pilecki B, Golen M: Pattern analysis of acute mucosal reactions in patients with head and neck cancer treated with conventional and accelerated irradiation. Int J Radiat Oncol Biol Phys. 2009, 73: 384-390. 10.1016/j.ijrobp.2007.12.057.View ArticlePubMedGoogle Scholar
- Hilario M, Kalousis A, Pellegrini C, Müller M: Processing and classification of protein mass spectra. Mass Spectrometry Review. 2006, 25: 409-449. 10.1002/mas.20072.View ArticleGoogle Scholar
- Pietrowska M, Marczak Ł, Polańska J, Behrendt K, Nowicka E, Walaszczyk A: Mass spectrometry-based serum proteome pattern analysis in molecular diagnostics of early stage breast cancer. J Translat Med. 2009, 7: e60-10.1186/1479-5876-7-60.View ArticleGoogle Scholar
- Pietrowska M, Polanska J, Suwinski R, Wideł M, Rutkowski T, Marczyk M: Comparison of peptide cancer signatures identified by mass spectrometry in serum of patients with head and neck, lung and colorectal cancers: association with tumor progression. Int J Oncol. 2012, 40: 148-156.PubMedGoogle Scholar
- Hastie T, Tibshirani R, Friedman JH: The Elements of Statistical Learning: Data Mining, Inference, and Prediction. 2009, New York: Springer VerlagView ArticleGoogle Scholar
- Lustgarten JL, Kimmel C, Ryberg H, Hogan W: EPO-KB: a searchable knowledge base of biomarker to protein links. Bioinformatics. 2008, 24: 1418-1419. 10.1093/bioinformatics/btn125.PubMed CentralView ArticlePubMedGoogle Scholar
- Pietrowska M, Polanska J, Marczak Ł, Behrendt K, Nowicka E, Stobiecki M: Mass spectrometry-based analysis of therapy-related changes in serum proteome patterns of patients with early stage breast cancer. J Translat Med. 2010, 8: e66-View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.